IDEXX Laboratories Inc (IDXX)
Return on equity (ROE)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 887,867 | 845,042 | 679,089 | 744,845 | 581,776 |
Total stockholders’ equity | US$ in thousands | 1,595,310 | 1,484,530 | 608,737 | 689,992 | 632,088 |
ROE | 55.65% | 56.92% | 111.56% | 107.95% | 92.04% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $887,867K ÷ $1,595,310K
= 55.65%
IDEXX Laboratories Inc's return on equity (ROE) has shown a positive trend over the past five years. The ROE increased from 92.04% on December 31, 2020, to 107.95% on December 31, 2021, further climbing to 111.56% by December 31, 2022.
However, there was a slight decline in ROE to 56.92% on December 31, 2023, followed by a further decrease to 55.65% by December 31, 2024. Despite the recent declines, IDEXX Laboratories Inc has maintained healthy ROE levels above 50% during this period, indicating efficient utilization of equity to generate profits for shareholders.
Investors and stakeholders should continue to monitor the company's ROE performance and consider factors driving these fluctuations to assess the sustainability of IDEXX Laboratories Inc's profitability and overall financial health.
Peer comparison
Dec 31, 2024